TR199802496T2 - Formulation for the treatment of congestive heart failure. - Google Patents
Formulation for the treatment of congestive heart failure.Info
- Publication number
- TR199802496T2 TR199802496T2 TR1998/02496T TR9802496T TR199802496T2 TR 199802496 T2 TR199802496 T2 TR 199802496T2 TR 1998/02496 T TR1998/02496 T TR 1998/02496T TR 9802496 T TR9802496 T TR 9802496T TR 199802496 T2 TR199802496 T2 TR 199802496T2
- Authority
- TR
- Turkey
- Prior art keywords
- heart failure
- congestive heart
- formulation
- treatment
- delayed release
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010007559 Cardiac failure congestive Diseases 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 230000003111 delayed effect Effects 0.000 abstract 2
- 239000007943 implant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Bu bulus, konjestif kalp yetmezligini, gecikmeli salinimli oral veya implant bir formülasyon ve gecikmeli salinimli formülasyonlar içindeki etkili dozdaThis invention relates to congestive heart failure, an oral or implant formulation with delayed release, and an effective dose of delayed release formulations.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65946396A | 1996-06-06 | 1996-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR199802496T2 true TR199802496T2 (en) | 1999-02-22 |
Family
ID=24645503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR1998/02496T TR199802496T2 (en) | 1996-06-06 | 1997-06-05 | Formulation for the treatment of congestive heart failure. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0914128A1 (en) |
| JP (1) | JP2000511906A (en) |
| KR (1) | KR20000016406A (en) |
| CN (1) | CN1226166A (en) |
| AU (1) | AU3233197A (en) |
| BR (1) | BR9709546A (en) |
| CA (1) | CA2256720A1 (en) |
| CZ (1) | CZ397698A3 (en) |
| EA (1) | EA199900006A1 (en) |
| HU (1) | HUP0003885A2 (en) |
| IL (1) | IL126966A0 (en) |
| NO (1) | NO985695L (en) |
| PL (1) | PL330637A1 (en) |
| TR (1) | TR199802496T2 (en) |
| WO (1) | WO1997046241A1 (en) |
| YU (1) | YU55998A (en) |
| ZA (1) | ZA974978B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19815411A1 (en) * | 1998-04-06 | 1999-10-07 | Solvay Pharm Gmbh | Thermogenesis stimulant comprising moxonidine, useful e.g. for treating hypothermia or promoting weight loss, having no cardiac stimulant side effects |
| AU2727400A (en) * | 1999-01-29 | 2000-08-18 | Eli Lilly And Company | Moxonidine salts |
| EP1150680B1 (en) * | 1999-02-01 | 2005-01-12 | Solvay Pharmaceuticals GmbH | Use of moxonidine for postmyocardial infarction treatment |
| EP1894927B1 (en) * | 2006-08-31 | 2010-11-10 | Chemagis Ltd. | The use of moxonidine salts for purification of moxonidine |
| KR100812287B1 (en) * | 2007-01-03 | 2008-03-13 | 주식회사 챠콜코리아 | Traffic light shade with reflective layer on the inside |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
| DE3617158C2 (en) * | 1986-05-22 | 1994-10-06 | Lohmann Therapie Syst Lts | Transdermal drug |
| DE3729299A1 (en) * | 1987-09-02 | 1989-03-23 | Beiersdorf Ag | TRANSDERMAL THERAPEUTIC SYSTEM |
| DE3904795C2 (en) * | 1989-02-17 | 2000-10-12 | Lilly Pharma Produktion Gmbh & | Pharmaceutical preparation and its use |
| DE4325491A1 (en) * | 1993-07-29 | 1995-02-02 | Boehringer Ingelheim Kg | Use of centrally acting alpha-2 agonists to inhibit post-aggression metabolism |
| DE4423177A1 (en) * | 1994-07-01 | 1996-01-04 | Kali Chemie Pharma Gmbh | Antihyperglycemic drugs |
| CA2182851A1 (en) * | 1995-08-15 | 1997-02-16 | August Masaru Watanabe | Method for treating substance abuse withdrawal |
-
1997
- 1997-06-05 KR KR1019980709980A patent/KR20000016406A/en not_active Withdrawn
- 1997-06-05 CN CN97196854A patent/CN1226166A/en active Pending
- 1997-06-05 PL PL97330637A patent/PL330637A1/en unknown
- 1997-06-05 TR TR1998/02496T patent/TR199802496T2/en unknown
- 1997-06-05 ZA ZA974978A patent/ZA974978B/en unknown
- 1997-06-05 WO PCT/US1997/009914 patent/WO1997046241A1/en not_active Ceased
- 1997-06-05 EP EP97928011A patent/EP0914128A1/en not_active Withdrawn
- 1997-06-05 AU AU32331/97A patent/AU3233197A/en not_active Abandoned
- 1997-06-05 CA CA002256720A patent/CA2256720A1/en not_active Abandoned
- 1997-06-05 JP JP10500901A patent/JP2000511906A/en active Pending
- 1997-06-05 BR BR9709546A patent/BR9709546A/en not_active Application Discontinuation
- 1997-06-05 IL IL12696697A patent/IL126966A0/en unknown
- 1997-06-05 HU HU0003885A patent/HUP0003885A2/en unknown
- 1997-06-05 CZ CZ983976A patent/CZ397698A3/en unknown
-
1998
- 1998-12-04 YU YU55998A patent/YU55998A/en unknown
- 1998-12-04 NO NO985695A patent/NO985695L/en not_active Application Discontinuation
-
1999
- 1999-01-06 EA EA199900006A patent/EA199900006A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA974978B (en) | 1998-12-07 |
| CZ397698A3 (en) | 1999-05-12 |
| EP0914128A1 (en) | 1999-05-12 |
| KR20000016406A (en) | 2000-03-25 |
| JP2000511906A (en) | 2000-09-12 |
| EA199900006A1 (en) | 1999-06-24 |
| BR9709546A (en) | 1999-08-10 |
| CA2256720A1 (en) | 1997-12-11 |
| HUP0003885A2 (en) | 2001-04-28 |
| PL330637A1 (en) | 1999-05-24 |
| CN1226166A (en) | 1999-08-18 |
| AU3233197A (en) | 1998-01-05 |
| YU55998A (en) | 1999-11-22 |
| NO985695D0 (en) | 1998-12-04 |
| WO1997046241A1 (en) | 1997-12-11 |
| IL126966A0 (en) | 1999-09-22 |
| NO985695L (en) | 1999-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0760848T3 (en) | Lactobacillus strains of human origin, their compositions and their use | |
| TR199802423T2 (en) | Concentrated antibody composition. | |
| TR200101793T2 (en) | Azabicycloalkanes as CCR5 modulators | |
| TR200101481T2 (en) | Cancer treatment composition and method using natural herbal essential oils. | |
| TR200101103T2 (en) | Controlled release pharmaceutical formulations containing CGMP PDE-Inhibitor | |
| YU60900A (en) | Novel crystalline forms of an antiviral benzimidazole compound | |
| CY2473B1 (en) | New phenanthridines. | |
| TR200100922T2 (en) | Application of active substances through the lungs. | |
| BR0314356A (en) | Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods using the same | |
| ATE400577T1 (en) | ANNATED DIHYDROPYRANS | |
| TR200100054T2 (en) | Paroxetine methanesulfonate | |
| TR200100172T2 (en) | Biologically strengthened formulations containing eprosartan in oral solid dosage form | |
| TR200102385T2 (en) | Self-dissolving N-benzoyl staurosporin compositions. | |
| TR199900505T2 (en) | ||
| DK0967987T3 (en) | Composition for the treatment of tumors containing shark cartilage extracts and anitneoplastic agents | |
| CA2408541A1 (en) | Treating eczema and/or psoriasis | |
| NO983177L (en) | Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer | |
| TR199802496T2 (en) | Formulation for the treatment of congestive heart failure. | |
| UA32598C2 (en) | Method for obtaining of carbamazepin dosage form | |
| TR200002847T2 (en) | Form VI 5, 6-dichloro-2- (isopropylamino) -1- (beta-L-ribofuranosyl) -1H-benzimidazole. | |
| TR200002939T2 (en) | Paroxetine maleate | |
| MD980129A (en) | Antiherpetic remedy | |
| DE50009821D1 (en) | Blondiermittel | |
| TR200100043T2 (en) | Derivatives of tetra hydropyridine (or 4-Hydroxypipeidine) -butylosolines in the preparation of drugs in the treatment of pain | |
| ATE232738T1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING COLOSTRUM AND THEIR USE |